[go: up one dir, main page]

ME03809B - KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a - Google Patents

KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a

Info

Publication number
ME03809B
ME03809B MEP-2020-160A MEP2020160A ME03809B ME 03809 B ME03809 B ME 03809B ME P2020160 A MEP2020160 A ME P2020160A ME 03809 B ME03809 B ME 03809B
Authority
ME
Montenegro
Prior art keywords
alkyl
compound
formula
unsubstituted
carbocyclyl
Prior art date
Application number
MEP-2020-160A
Other languages
German (de)
English (en)
French (fr)
Inventor
Botella Gabriel Martinez
Francesco G Salituro
Albert Jean Robichaud
Boyd L Harrison
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of ME03809B publication Critical patent/ME03809B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (19)

1. Jedinjenje formule (I): ili njegova farmaceutski prihvatljiva so, u kome:A je 3-10 -člani heterociklil ili monociklični ili biciklični heteroaril;R1 je nesupstituisanC1-6 alkil ili -haloalkil;R2a je nesupstituisanC1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;ili R2a i R2b zajedno sa atomom ugljenika za koji su vezani formiraju 3-6-člani karbociklil ili heterociklil prsten;R3 je otsutan ili je vodonik; ipredstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan; gde je heterociklil ili heteroaril nesupstituisan; ili susptituisan sa najmanje jednim RA, gde je RA jednako C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6 ili S(=O)2RB6, gde je RA6 jednako vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, ili C1-6 haloalkil, i RB6 je C1-6 alkil ili C3-6 karbociklil.
2. Jedinjenje prema patentnom zahtevu 1,i) pri čemu, jedinjenje formule (I) je jedinjenje formule (II) ili formule (III): ili njegova farmaceutski prihvatljiva so;ii) pri čemu, jedinjenje formule (I) je jedinjenje formule (II-a) ili formule (II-b): ili njegova farmaceutski prihvatljiva so; iliiii) pri čemu, jedinjenje formule (I) je jedinjenje formule (III-a) ili formule (III-b): ili njegova farmaceutski prihvatljiva so,i pri čemu A, R1, R2a, i R2b su definisani kao za formulu (I).
3. Jedinjenje prema patentnom zahtevu 1 formule (IV): ili njegova farmaceutski prihvatljiva so u kome:A je 3-10 člani heterociklil ili monocikličan ili bicikličan heteroaril;R1 je nesupstituisanC1-6 alkil ili -haloalkil;R2a je nesupstituisanC1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;R3 je otsutan ili je vodonik;RA je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6 ili S(=O)2RB6, gde RA6 je vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, ili C1-6 haloalkil, i RB6 je C1-6 alkil ili C3-6 karbociklil;n je 0, 1, 2 ili 3; ipredstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan;pri čemu heterociklil, heteroaril, C1-6 alkil, karbociklil, C2-6 alkenil, C2-6 alkinil i C1-6 haloalkil grupe mogu biti supstituisane ili nesupstituisane.
4. Jedinjenje prema patentnom zahtevu 3,i) pri čemu, jedinjenje formule (IV) je jedinjenje formule (V) ili formule (VI): ili njegova farmaceutski prihvatljiva so; iliii) pri čemu, jedinjenje formule (IV) je jedinjenje formule (V-a) ili formule (V-b): ili njegova farmaceutski prihvatljiva so; iliiii) pri čemu, jedinjenje formule (IV) je jedinjenje formule (VI-a) ili formule (VI-b): ili njegova farmaceutski prihvatljiva so,i pri čemu A, R1, R2a, R2b, RA i n su definisani kao za formulu (IV).
5. Jedinjenje prema bilo kom od patentnih zahteva, naznačen time što R1 je metil ili CF3.
6. Jedinjenje prema bilo kom od patentnih zahteva, naznačen time što R2a je metil.
7. Jedinjenje prema bilo kom od patentnih zahteva, naznačen time što R2a je metil i R2b je vodonik.
8. Jedinjenje prema bilo kom od patentnih zahteva, naznačen time što A je supstituisan sa 1-3 slučaja RA.
9. Jedinjenje prema bilo kom od prethodnih patentnih zahteva, naznačeno time štoi) A je izabran od: i iliii) pri čemu je A izabran od:i
10. Jedinjenje prema bilo kom od patentnih zahteva, naznačen time što je jedinjenje izabrano od: i ili njegova farmaceutski prihvatljiva so.
11. Farmaceutska kompozicija koja sadrži:jedinjenje prema bilo kom od prethodnih patentnih zahteva i farmaceutski prihvatljiv ekscipijens.
12. Jedinjenje formule (I), za upotrebu u postupku za indukciju sedacije i/ili anestezije kod subjekta, koji sadrži primenu na subjekta efikasne količine jedinjenja formule (I): ili njegove farmaceutski prihvatljive soli, u kome:A je 3-10 člani heterociklil ili monocikličan ili bicikličan heteroaril;R1 je nesupstituisan C1-6 alkil ili -haloalkil;R2a je nesupstituisan C1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;ili R2a i R2b zajedno sa atomom ugljenika za koji su vezani formiraju 3-6-člani karbociklil ili heterociklil prsten;R3 je otsutan ili je vodonik; ipredstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan, pri čemu heterociklil ili heteroaril je nesupstituisan; ili supstituisan sa najmanje jednim RA, pri čemu RA je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6 ili S(=O)2RB6, pri čemu RA6 je vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil ili C1-6 haloalkil, iRB6 je C1-6 alkil ili C3-6 karbociklil; iizborno pri čemu se jedinjenje primenjuje u kombinaciji sa drugim terapeutskim sredstvom, pri čemu subjekat oseća sedaciju i/ili anesteziju; pri čemu subjekat oseća sedaciju i/ili anesteziju u roku od dva časa od primene; ili pri čemu subjekat oseća sedaciju i/ili anesteziju u roku od jednog časa od primene; ili pri čemu subjekat oseća sedaciju i/ili anesteziju odmah.
13. Jedinjenje za upotrebu prema patentnom zahtevu 12, naznačeno time što se jedinjenje primenjuje intravenskom primenom, ili pri čemu se jedinjenje primenjuje hronično.
14. Jedinjenje za upotrebu prema patentnom zahtevu 13, naznačeno time što je subjekat sisar npr. čovek.
15. Jedinjenje formule (I), za upotrebu u postupku za lečenje napada kod subjekta, koji sadrži primenu na subjekta efikasne količine jedinjenja formule (I): ili njegove farmaceutski prihvatljive soli, u kome:A je 3-10 -člani heterociklil ili monociklični ili biciklični heteroaril;R1 je nesupstituisanC1-6 alkil ili haloalkil;R2a je nesupstituisanC1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;ili R2a i R2b zajedno sa atomom ugljenika za koji su vezani formiraju 3-6-člani karbociklil ili heterociklil prsten;R3 je otsutan ili je vodonik;predstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan; i pri čemu heterociklil ili heteroaril je nesupstituisan; ili supstituisan sa najmanje jednim RA, pri čemu, RA je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6, ili S(=O)2RB6, pri čemu, RA6 je vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil ili C1-6 haloalkil, iRB6 je C1-6 alkil ili C3-6 karbociklil.
16. Jedinjenje formule (I), za upotrebu u postupku za lečenje epilepsije ili status epilepticus-a kod subjekta, pri čemu postupak sadrži primenu na subjekta efikasne količine jedinjenja formule (I): ili njegove farmaceutski prihvatljive soli, u kome:A je 3-10 -člani heterociklil ili monociklični ili biciklični heteroaril;R1 je nesupstituisanC1-6 alkil ili -haloalkil;R2a je nesupstituisan C1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;ili R2a i R2b zajedno sa atomom ugljenika za koji su vezani formiraju 3-6-člani karbociklil ili heterociklil prsten;R3 je otsutan ili je vodonik;predstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan; i pri čemu, heterociklil ili heteroaril je nesupstituisan; ili supstituisan sa najmanje jednim RA, pri čemu, RA je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6 ili S(=O)2RB6, pri čemu, RA6 je vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil ili C1-6 haloalkil, i RB6 je C1-6 alkil ili C3-6 karbociklil.
17. Jedinjenje formule (I), za upotrebu u postupku za lečenje poremećaja kod subjekta kod koga postoji potreba za tim, koji sadrži primenu na subjekta efikasne količine jedinjenja formule (I): ili njegove farmaceutski prihvatljive soli, u kome:A je 3-10 -člani heterociklil ili monociklični ili biciklični heteroaril;R1 je nesupstituisan C1-6 alkil ili -haloalkil;R2a je nesupstituisanC1-6 alkil;R2b je vodonik ili nesupstituisan C1-6 alkil;ili R2a i R2b su spojeni tako da formiraju okso (=O) grupu;ili R2a i R2b zajedno sa atomom ugljenika za koji su vezani formiraju 3-6-člani karbociklil ili heterociklil prsten;R3 je otsutan ili je vodonik;predstavlja jednogubu ili dvogubu vezu, pri čemu, kada je jedan od dvoguba veza, drugi je jednoguba veza; i kada je jedan od dvoguba veza, R3 je otsutan;pri čemu, heterociklil ili heteroaril je nesupstituisan; ili supstituisan sa najmanje jednim RA, pri čemu, RA je C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, C1-6 haloalkil, halogen, cijano, -ORA6, -C(=O)ORA6, -SRB6, -S(=O)RB6, ili S(=O)2RB6, pri čemu, RA6 je vodonik ili C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C3-6 karbociklil, ili C1-6 haloalkil, i RB6 je C1-6 alkil ili C3-6 karbociklil; ipri čemu, poremećaj je poremećaj povezan sa CNS-om izabran od poremećaja spavanja, poremećaja ishrane, poremećaja raspoloženja, poremećaj spektra šizofrenije, konvulzivni poremećaj, poremećaj pamćenja i/ili kognicije, poremećaj kretanja, poremećaj ličnosti, poremećaj spektra autizma, bol, traumatska povreda mozga, vaskularna bolest, poremećaj zloupotrebe supstance i/ili apstinencijalni sindrom, ili tinitus; ili pri čemu, poremećaj je depresija ili postpartalna depresija; ili pri čemu, poremećaj povezan sa CNS-om je tremor ili esencijalni tremor; ili pri čemu, poremećaj povezan sa CNS-om je anoreksija nervoza, bulimija nervoza, poremećaj opsesivnog prejedanja ili kaheksija.
18. Jedinjenje za upotrebu prema patentnom zahtevu 17, naznačeno time što se jedinjenje primenjuje oralno ili intramuskularno.
19. Jedinjenje za upotrebu prema patentnom zahtevu 17, naznačeno time što, subjekat je subjekat sa Rett-ovim sindromom, sindromom fragilnog X ili Angelman-ovim sindromom.
MEP-2020-160A 2014-10-16 2015-10-16 KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a ME03809B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064957P 2014-10-16 2014-10-16
EP15851053.7A EP3206493B1 (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders
PCT/US2015/056066 WO2016061537A1 (en) 2014-10-16 2015-10-16 Compositions and methods for treating cns disorders

Publications (1)

Publication Number Publication Date
ME03809B true ME03809B (me) 2021-04-20

Family

ID=55747454

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2020-160A ME03809B (me) 2014-10-16 2015-10-16 KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a

Country Status (18)

Country Link
US (5) US20170233433A1 (me)
EP (3) EP3206493B1 (me)
JP (3) JP6742308B2 (me)
AU (3) AU2015331597B2 (me)
CY (1) CY1123246T1 (me)
DK (1) DK3206493T3 (me)
ES (1) ES2808855T3 (me)
HR (1) HRP20201216T1 (me)
HU (1) HUE051488T2 (me)
LT (1) LT3206493T (me)
ME (1) ME03809B (me)
NZ (1) NZ769042A (me)
PL (1) PL3206493T3 (me)
PT (1) PT3206493T (me)
RS (1) RS60642B1 (me)
SI (1) SI3206493T1 (me)
SM (1) SMT202000414T1 (me)
WO (1) WO2016061537A1 (me)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
LT2887944T (lt) 2012-08-21 2022-01-10 Sage Therapeutics, Inc. Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
PT3498725T (pt) 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
RU2700264C2 (ru) 2013-04-17 2019-09-16 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
HUE059829T2 (hu) * 2014-05-29 2022-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítményeik és alkalmazásuk
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN118344424A (zh) 2014-10-16 2024-07-16 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
LT3206493T (lt) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2992037T3 (es) * 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
NZ790226A (en) * 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11236121B2 (en) * 2016-08-23 2022-02-01 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
EP4218767A1 (en) * 2017-09-14 2023-08-02 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
EP3720867A1 (en) * 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
IL275562B2 (en) * 2017-12-22 2024-07-01 Sage Therapeutics Inc Compositions and methods for treating cns disorders
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
ES3018614T3 (es) 2018-02-11 2025-05-16 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores derivados de esteroides, método para prepararlos y usos de los mismos
CN114656514B (zh) 2018-02-11 2024-05-14 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
EP3806863A1 (en) * 2018-06-12 2021-04-21 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
BR112021011765A2 (pt) 2018-12-17 2021-08-31 Intra-Cellular Therapies, Inc. Compostos orgânicos
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7726867B6 (ja) 2019-08-07 2025-09-18 上▲海▼翰森生物医▲薬▼科技有限公司 ステロイド誘導体調節因子の塩及び結晶形態
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
TW202143976A (zh) * 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
CN115551514A (zh) 2020-03-25 2022-12-30 萨奇治疗股份有限公司 用于治疗呼吸系统病症的药物的用途
CA3198628A1 (en) * 2020-10-17 2022-04-21 Cornell University Methods for controlling and predicting recovery after nmba administration

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856415A (en) 1957-11-13 1958-10-14 Searle & Co 3,19-dihydroxy-5-androstene derivatives
FR1380417A (fr) 1962-05-15 1964-12-04 Roussel Uclaf Nouveaux androstanyl-pyrazoles et procédé de préparation
US3206459A (en) 1962-10-19 1965-09-14 Syntex Corp 10alpha-pregnan-19-ol derivatives
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1434919A (en) 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes
GB1380246A (en) 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
GB1436324A (en) 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
DK134348C (da) 1973-11-30 1977-03-21 Schering Ag Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
DE2438020A1 (de) 1974-08-05 1976-02-26 Schering Ag 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
DE2526373C2 (de) 1975-06-11 1983-11-10 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
DE2632677A1 (de) 1976-07-16 1978-01-26 Schering Ag Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung
GB1581235A (en) 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4389345A (en) 1981-10-09 1983-06-21 G.D. Searle & Co. 3-Oxoestra-17-acetonitrile and unsaturated analogs
US4495102A (en) 1982-09-03 1985-01-22 G. D. Searle & Co. Aminoalkyl steroids
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH06510999A (ja) 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
JP4008024B2 (ja) * 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
CZ300694A3 (en) 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CA2183231A1 (en) 1994-02-14 1995-08-17 Ravindra B. Upasani Androstanes and pregnanes for allosteric modulation of gaba receptor
JP2002500616A (ja) 1994-07-21 2002-01-08 ファルマシア・アンド・アップジョン・カンパニー 神経学的に活性なアミノステロイド
DK0808325T3 (da) * 1994-11-23 2001-01-29 Cocensys Inc Androstan- og pregnanserier til allosterisk modulering af GABA-receptor
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US5935545A (en) 1997-07-11 1999-08-10 E. I. Du Pont De Nemours And Company Process for producing an aqueous solution comprising ferric chloride
YU77701A (sh) 1999-04-29 2005-07-19 Euro-Celtique S.A. 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
US7018406B2 (en) 1999-11-17 2006-03-28 Corevalve Sa Prosthetic valve for transluminal delivery
DE60111304T2 (de) 2000-02-18 2005-11-10 Taiho Pharmaceutical Co. Ltd. Verfahren zur herstellung von steroid-derivaten
US6855836B2 (en) 2000-10-26 2005-02-15 Jenapharm Gmbh & Co. Kg 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds
EP1330467B1 (en) 2000-11-03 2007-05-02 Washington University Modified, hydroxy-substituted aromatic structures having cytoprotective activity
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
DK1608671T3 (da) 2003-03-24 2010-05-10 Sterix Ltd Østrogenderivater som inhibitorer af steroidsulfatase
WO2005000869A1 (en) 2003-05-29 2005-01-06 Washington University Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids
US20070099880A1 (en) 2003-11-24 2007-05-03 Blizzard Timothy A Estrogen receptor modulators
US20090118248A1 (en) 2004-04-23 2009-05-07 Euro-Celtique S.A. 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
SI1888080T1 (sl) 2005-06-09 2010-08-31 Euro Celtique Sa Farmacevtski sestavki nevroaktivnega steroida in njegove uporabe
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
DE102007027636A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
JP5663303B2 (ja) 2007-06-15 2015-02-04 リサーチ トライアングル インスティテュート Ｇａｂａレセプタークロライドイオノフォアの潜在的アロステリック調節特性を有するアンドロスタンステロイドおよびプレグナンステロイド
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
CN101412742B (zh) 2007-10-19 2013-07-31 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
US20090264443A1 (en) 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101624414B (zh) 2008-07-07 2013-02-13 天津金耀集团有限公司 一种抑制血管新生的硝酸酯药物
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
WO2010054158A2 (en) 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
WO2012013816A1 (en) 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
US20120214987A1 (en) 2010-12-15 2012-08-23 Yu Ge Methods and compounds for preparing 3alpha-oxygen substituted steroids
CZ201181A3 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
CA2828047C (en) 2011-02-15 2020-03-10 Socpra Sciences Et Genie, S.E.C. Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
ES2657986T3 (es) 2011-03-23 2018-03-07 Etsuro Ito Método y kit para la medición de muy alta sensibilidad de proteína y ácido nucleico y un novedoso sustrato enzimático
WO2013019711A2 (en) 2011-07-29 2013-02-07 The Regents Of The University Of California NOVEL 17β-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
AU2012304412A1 (en) 2011-09-08 2014-03-27 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3789394A1 (en) 2012-06-19 2021-03-10 Intercept Pharmaceuticals, Inc. Crystalline forms c of obeticholic acid
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2916846B1 (en) 2012-11-09 2025-09-17 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US9676812B2 (en) 2012-12-18 2017-06-13 Washington University Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
US8939545B2 (en) 2012-12-20 2015-01-27 Eastman Kodak Company Inkjet printing with managed airflow for condensation control
CA2831054C (en) 2013-01-09 2016-08-30 Sapna Life Sciences Corp. Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
GB201302368D0 (en) 2013-02-11 2013-03-27 Univ Bath Compound
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
RU2700264C2 (ru) 2013-04-17 2019-09-16 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
PT3498725T (pt) 2013-04-17 2021-09-09 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3-dissubstituídos para uso em terapia
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
HUE059829T2 (hu) 2014-05-29 2022-12-28 Sage Therapeutics Inc Neuroaktív szteroidok, készítményeik és alkalmazásuk
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA40498A (fr) 2014-09-02 2021-05-19 Texas A & M Univ Sys Méthode de traitement de l'intoxication par organophosphates
CN118344424A (zh) 2014-10-16 2024-07-16 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
LT3206493T (lt) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
EP3224269B1 (en) 2014-11-27 2020-02-26 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP6745274B2 (ja) 2015-01-26 2020-08-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
CN105985396A (zh) 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
UY36741A (es) 2015-06-21 2016-12-30 Prevacus Inc Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales
WO2017044659A1 (en) 2015-09-08 2017-03-16 Viewpoint Therapeutics, Inc. Compounds and formulations for treating ophthalmic diseases
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
EP3377070A4 (en) 2015-11-20 2019-07-10 Sage Therapeutics, Inc. COMPOUNDS AND METHOD FOR THEIR USE
CN109414444A (zh) 2016-03-08 2019-03-01 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
ES2992037T3 (es) 2016-07-11 2024-12-05 Sage Therapeutics Inc Esteroides neuroactivos sustituidos en C7, C12 y C16 y sus procedimientos de utilización
NZ790226A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
US11236121B2 (en) 2016-08-23 2022-02-01 Sage Therapeutics, Inc. Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
CN111065394B (zh) 2017-08-31 2023-03-31 武田药品工业株式会社 中枢神经系统病症的治疗
CN111491637A (zh) 2017-09-07 2020-08-04 萨奇治疗股份有限公司 神经活性甾类及其使用方法
EP3706755A4 (en) 2017-11-10 2021-11-10 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF GENETIC EPILEPTIC DISEASES
CN112823164A (zh) 2018-05-04 2021-05-18 阿克罗斯制药公司 神经甾体衍生物和其用途

Also Published As

Publication number Publication date
EP3206493A4 (en) 2018-04-04
HUE051488T2 (hu) 2021-03-01
US20250236638A1 (en) 2025-07-24
AU2022203444B2 (en) 2024-03-14
JP2022116318A (ja) 2022-08-09
WO2016061537A1 (en) 2016-04-21
EP3753927A1 (en) 2020-12-23
LT3206493T (lt) 2020-08-25
AU2020207810B2 (en) 2022-02-24
JP7085592B2 (ja) 2022-06-16
EP4275748A3 (en) 2024-01-03
EP4275748A2 (en) 2023-11-15
DK3206493T3 (da) 2020-08-10
RS60642B1 (sr) 2020-09-30
US12180248B2 (en) 2024-12-31
NZ731095A (en) 2023-12-22
CY1123246T1 (el) 2021-10-29
JP7510461B2 (ja) 2024-07-03
US20170233433A1 (en) 2017-08-17
AU2015331597A1 (en) 2017-05-11
US20210087223A1 (en) 2021-03-25
PL3206493T3 (pl) 2021-01-25
EP3206493B1 (en) 2020-05-06
SI3206493T1 (sl) 2020-10-30
HRP20201216T1 (hr) 2020-12-11
US10870677B2 (en) 2020-12-22
JP6742308B2 (ja) 2020-08-19
US20230192757A1 (en) 2023-06-22
EP3753927B1 (en) 2023-07-19
JP2020183434A (ja) 2020-11-12
SMT202000414T1 (it) 2020-09-10
NZ769042A (en) 2023-12-22
JP2017531020A (ja) 2017-10-19
ES2808855T3 (es) 2021-03-02
AU2020207810A1 (en) 2020-08-06
PT3206493T (pt) 2020-08-03
AU2015331597B2 (en) 2020-04-30
CA2964898A1 (en) 2016-04-21
EP3206493A1 (en) 2017-08-23
AU2022203444A1 (en) 2022-06-09
US20200024301A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
ME03809B (me) KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
HRP20210344T1 (hr) Pripravci i postupci liječenja poremećaja cns
JP2017531020A5 (me)
PH12016502342A1 (en) Neuroactive steroids, compositions, and uses thereof
UA110347C2 (uk) ПОХІДНІ 6-ЦИКЛОАЛКІЛ-1,5-ДИГІДРОПІРАЗОЛО[3,4-d]ПІРИМІДИН-4-ОНУ І ЇХ ЗАСТОСУВАННЯ ЯК ІНГІБІТОРІВ PDE9A
TR201904614T4 (en) Novel pyrazole derivative.
HRP20211282T1 (hr) Oksisteroli i postupci njihovog korištenja
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
EA201071298A1 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, его содержащая, и способ их получения
HRP20210526T1 (hr) Oksisteroli i postupci za njihovu uporabu
WO2020112941A3 (en) Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
HRP20201171T1 (hr) Derivati izoindolin-1-ona kao modulatori aktivnosti pozitivnog alosternog modulatora kolinergijskog muskarinskog m1 receptora za liječenje alzheimerove bolesti
JP2018511647A5 (me)
RU2018106483A (ru) Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
EA201370184A1 (ru) Гетероарильные производные
RU2015140669A (ru) Пиридинилпиразолохинолиновые соединения
WO2017177004A8 (en) Tertiary amides and method of use
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
TN2020000161A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
HRP20151419T1 (hr) Derivati 2-okso-1-imidazolidinil imidazotiadiazola
EA200970553A1 (ru) Пиперидиниламинопиридазины и их применение в качестве быстро диссоциирующих антагонистов рецептора допамина 2
JP2017536410A5 (me)
FI3541784T3 (fi) Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
RU2018130994A (ru) Новое соединение бисфосфоновой кислоты
NZ731095B2 (en) Compositions and methods for treating cns disorders